Publication | Closed Access

Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium

Non-valvular Atrial FibrillationPharmacotherapyThrombosisStrokePublic HealthPlatelet AntagonistApixaban Versus AspirinCardiologyAtherosclerosisHealth PolicyCost EffectivenessCardiovascular DiseasePatient SafetyStroke-related ConditionCoagulopathyMedicineAnticoagulantEmergency MedicineAnesthesiology